559.00p
+2.38%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oxford Biomedica
Its shares trade on LSE under the ticker OXB.L. It has been listed since 15 November 1996. In the fiscal year to 31 December 2025, it reported revenue of £168.7m and a net loss of £30.1m. At that date it held total assets of £325.7m and shareholders' equity of £91.3m.
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Nov 1996
- Employees
- 500
- Website
- oxfordbiomedica.co.uk ↗
Leadership
Pay as last reported
- Dr. Roch DoliveuxIndependent Non-Executive Chairman of the Board, since 2020£225,000
- Dr. Frank MathiasChief Executive Officer, Executive Director, since 2023£1.1m
- Mr. Stuart HendersonIndependent Non-Executive Vice Chairman of the Board£85,000
- Dr. Lucinda CrabtreeChief Financial Officer, Executive Director, since 2024£235,000
- Mr. Thierry CournezChief Operating Officer, Site Head of UK Operations
- Ms. Lisa DomanChief People Officer
- Ms. Natalie WalterGroup General Counsel, Company Secretary
- Dr. Kyriacos MitrophanousChief Innovation Officer
- Dr. Sebastien RibaultChief Business Officer
- Dr. Sabine SydowChief Of Staf
- Mr. Colin BondIndependent Non-Executive Director
- Ms. Laurence EspinasseNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 72
- Social
- 99
- Governance
- 52
- Direct emissions (scope 1)
- 2,269 t
- Energy emissions (scope 2)
- 3,055 t
- Value chain emissions (scope 3)
- 78,525 t
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Oxford BioMedica PLC has built a strong reputation in the biotech industry for its advanced gene and cell therapy development.
- Strong Intellectual Property Portfolio: The company possesses a robust patent portfolio, providing protection for its innovative technologies and potential for licensing opportunities.
- Strategic Partnerships: Oxford BioMedica has established collaborations with leading pharmaceutical companies, enabling access to shared resources, expertise, and potential commercialization opportunities.
- Successful Clinical Trials: The company has achieved positive results in various clinical trials, validating the efficacy and safety of its therapies.
- Diversified Revenue Streams: Oxford BioMedica has multiple revenue sources including licensing agreements, commercial supply agreements, and government grants, reducing dependency on a single source.
Weaknesses
- Reliance on Partnerships: The company heavily depends on collaborations with pharmaceutical partners, making it vulnerable to any changes or disruptions in these partnerships.
- Limited Product Portfolio: Oxford BioMedica's product pipeline is relatively limited, with a focus on gene and cell therapies. This lack of diversification may expose the company to market fluctuations and reduced growth opportunities.
- High Research and Development Costs: The development of innovative therapies requires significant investment, putting financial strain on the company, especially if progress in clinical trials is slow.
- Regulatory Challenges: The biotech industry is subject to strict regulations and approval processes, which can cause delays and uncertainties in bringing new therapies to the market.
Opportunities
- Growing Demand for Gene and Cell Therapies: The increasing prevalence of genetic and rare diseases provides a significant market opportunity for Oxford BioMedica's specialized therapies.
- Expansion into New Markets: The company can explore expansion opportunities in emerging markets, where the demand for advanced biotechnological treatments is rapidly growing.
- Advances in Technology: Ongoing advancements in gene editing and cell therapy technologies present opportunities for Oxford BioMedica to develop more efficient and precise therapies.
- Strategic Collaborations: Forming additional partnerships with pharmaceutical companies or research institutions can enhance research capabilities, expand the product pipeline, and drive revenue growth.
- Government Support: Government initiatives and funding for research and development in the biotech sector can provide financial support and favorable regulatory environments for Oxford BioMedica's operations.
Threats
- Intense Competition: The biotech industry is highly competitive, with numerous companies vying to develop innovative therapies, posing a threat to Oxford BioMedica's market share.
- Patent Expirations: The expiration of key patents may result in increased competition and potential revenue loss for Oxford BioMedica, especially if competitors launch similar therapies.
- Clinical Trial Risks: Clinical trials inherently carry risks of unexpected adverse events or failure to meet desired endpoints, which could lead to setbacks in product development.
- Economic Downturns: Economic uncertainties and recessions may impact healthcare spending and investment in new therapies, potentially affecting Oxford BioMedica's financial performance.
- Ethical and Regulatory Concerns: The ethical considerations surrounding gene editing and cell therapy raise public skepticism and regulatory challenges, potentially hindering market acceptance and commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.